

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/830,977	07/31/2001	Stefan Ambs	15280-3581US	7226
7590 02/01/2005			EXAMINER	
Annette S Parent			HUFF, SHEELA JITENDRA	
Townsend and I	Townsend and Crew			
Two Embarcadero Center 8th Floor			ART UNIT	PAPER NUMBER
San Francisco,	CA 94111-3834		1642	
			DATE MAILED: 02/01/2005	5

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
	09/830,977	AMBS ET AL.		
Office Action Summary	Examiner	Art Unit		
<u></u>	Sheela J Huff	1642		
The MAILING DATE of this communication Period for Reply	on appears on the cover sheet with	th the correspondence address		
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNICATORY Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communicatory of the period for reply specified above is less than thirty (30) day of the If NO period for reply is specified above, the maximum statutory of Failure to reply within the set or extended period for reply will, the Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	CFR 1.136(a). In no event, however, may a relation.  ys, a reply within the statutory minimum of thirty period will apply and will expire SIX (6) MON' by statute, cause the application to become AB.	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).		
Status				
1) Responsive to communication(s) filed or	n 28 December 2004.			
	This action is non-final.			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits				
closed in accordance with the practice u	·	·		
Disposition of Claims				
<ul> <li>4) ☐ Claim(s) 1-10 is/are pending in the applitude 4a) Of the above claim(s) is/are w</li> <li>5) ☐ Claim(s) is/are allowed.</li> <li>6) ☐ Claim(s) 1-4,7,8 and 10 is/are rejected.</li> <li>7) ☐ Claim(s) 5-69 is/are objected to.</li> <li>8) ☐ Claim(s) are subject to restriction</li> </ul>	ithdrawn from consideration.			
Application Papers				
9)☐ The specification is objected to by the Ex	raminer.			
10) The drawing(s) filed on is/are: a)	☐ accepted or b)☐ objected to b	by the Examiner.		
Applicant may not request that any objection	to the drawing(s) be held in abeyan	ce. See 37 CFR 1.85(a).		
Replacement drawing sheet(s) including the				
11) The oath or declaration is objected to by	the Examiner. Note the attached	Office Action or form PTO-152.		
Priority under 35 U.S.C. § 119				
<ul> <li>12) Acknowledgment is made of a claim for f</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority doc</li> <li>2. Certified copies of the priority doc</li> <li>3. Copies of the certified copies of the application from the International</li> </ul>	uments have been received. uments have been received in Ap ne priority documents have been	pplication No		
* See the attached detailed Office action for	r a list of the certified copies not	received.		
	•			
Attachment(s)				
1) Notice of References Cited (PTO-892)	4) Interview S	summary (PTO-413)		
2) Notice of Draftsperson's Patent Drawing Review (PTO-9		s)/Mail Date Informal Patent Application (PTO-152)		
<ol> <li>Information Disclosure Statement(s) (PTO-1449 or PTO Paper No(s)/Mail Date</li> </ol>	/SB/08) 5)   Notice of in	* * * * * * * * * * * * * * * * * * * *		

Application/Control Number: 09/830,977

Art Unit: 1642

#### **DETAILED ACTION**

### Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 12/28/04 has been entered.

Claims 1-10 are pending.

Claims 11-22 are cancelled.

## Response to Arguments

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-4 and 10 remain rejected under 35 U.S.C. 102(a) as being anticipated by Reiger et al Oncogene vol. 17 p. 2323 (11/5/98). The reasons for this rejection are of record in the paper mailed 2/9/04.

Applicant argues that the screening process is "naturally and logically associated with the experiments" of the 8/3/04 declaration (see supplemental declaration). All applicant shows in the declaration is that one compound is a NOS2 inhibitor. Merely

**Art Unit: 1642** 

showing one compound as an inhibitor does not contemplate a screening process. A screening process is screening a multitude of different compounds for a certain activity and identifying which compound(s) possess said activity. A mere statement that the showing of one compound as an inhibitor and that a screening assay naturally follows does not constitute objective evidence.

Applicant also argues that the difference identity of the NOS2 inhibitor as compared that those in the reference has no bearing on the scope of the claimed invention and states that submitting reduction to practice of one compound is sufficient and that the "screening assay" applies to any and all NOS2 modulators (see supplemental declaration (paragraph 5)). As stated above, applicant has not demonstrated a screening assay.

Applicant further cites MPEP 715.02 and 715.03 and states that the MPEP does not impose a strict requirement for the subject matter in the declaration and the reference be the same. The Examiner never said it did. Again, applicant is directed to MPEP 715.03 which states "where generic claims have been rejected on a reference or activity which discloses a species not antedated by the affidavit or declaration, the rejection will not ordinarily be withdrawn, unless the applicant is able the establish that he or she was in possession of the generic invention prior to the effective date of the reference or activity." (emphasis added). Applicant has not demonstrated that he had possession of the generic invention prior to the effective date.

Application/Control Number: 09/830,977

Art Unit: 1642

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claim 8 remains rejected under 35 U.S.C. 103(a) as being unpatentable over Reiger et al Oncogene vol. 17 p. 2323 (11/5/98) in view of applicant admission on page

17, lines 26-31 of the specification). The reasons for this rejection are of record in the paper mailed 2/9/04.

Applicant's arguments have been addressed above.

# Allowable Subject Matter

Claims 5-6 and 9 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### **Conclusion**

This is a RCE of applicant's earlier Application No. 09/830977. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 1642

the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheela J Huff whose telephone number is 571-272-0834. The examiner can normally be reached on Mondays and Thursdays from 5:30am to 2:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

> Ahula Jus Sheela J Huff **Primary Examiner**

Art Unit 1642

sjh